^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

BRG01

i
Other names: BRG01
Company:
Biosyngen
Drug class:
T-cell stimulant
6ms
A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (clinicaltrials.gov)
P1, N=14, Completed, BioSyngen Pte Ltd | Trial completion date: Jan 2028 --> Apr 2024 | Trial primary completion date: Jan 2028 --> Apr 2024 | Not yet recruiting --> Completed
Trial completion • Trial completion date • Trial primary completion date • Metastases
|
BRG01
over1year
New P1 trial • Metastases
|
BRG01